PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...
4don MSN
PDS Biotech outlines trial protocol amendment for accelerated PFS endpoint in HPV16-positive cancer
Get key insights from PDS Biotech’s Q3 2025 earnings call, including regulatory updates for PDS0101 in HPV16+ cancer and financial highlights.
PDS Biotechnology ( ($PDSB) ) just unveiled an update. On November 11, 2025, PDS Biotechnology Corporation announced a securities purchase ...
TipRanks on MSN
PDS Biotechnology Announces Positive Data at Cancer Meeting
The latest announcement is out from PDS Biotechnology ( (PDSB) ).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback